


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:


1. (Currently Amended) A method for preventing or treating dementia, the method comprising:


~~use of providing a derivatives derivative of a succinate esters ester of general formula (I) in the manufacture of the medicine for preventing or treating dementia:~~





(I)

wherein,

R₁ and R₄ are selected from -OCH₃, -OH, -O-Glu, , and



R₂ and R₃ are selected from H, -OH, -O-Glu, , and




R₅ is selected from non-branched or branched C₁₋₆ alkyls; and

[[The]] the configuration of chiral center at C-2 and C-3 are 2R3S, 2R3R, 2S3S and 2S3R respectively; and

administering the succinate ester derivative to a patient.



2. (Currently Amended) The method according to claim 1, characterized in that said compound of formula (I) is:








(I)


Wherein R₅ is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl; and R₁, R₂, R₃, and R₄ are the same as that in claim 1.

3. (Currently Amended) The method according to claim 2 characterized in that said compounds include:










Response to Office Action Mailed May 8, 2007



1,4-bis(β-D-glucopyranosyloxybenzyl)-2-β-D-glucopyranosyl-2-isobutylmalate (dactylorhin A)
(W8);





4. (Currently Amended) The [[use]] method according to claim 1, characterized in that said compounds include stereo-isomers and pharmaceutical acceptable salts.

5. (Currently Amended) The [[use]] method according to claim 1, characterized in that said dementia includes Alzheimer' disease, vascular dementia, and learning and memory obstacle.

6. (Currently Amended) A pharmaceutical composition, comprising an effective amount of any one of the compounds according to claim 1 and a pharmaceutically acceptable carrier, wherein the pharmaceutically effective carrier is not water.

7. (Previously presented) The pharmaceutical composition according to claim 6, characterized in that said pharmaceutical composition may be in the form of tablets, capsules, pills, injectable solutions, sustained released formulation, controlled released formulation and various microparticle systems.

8. (Currently Amended) ~~An use of~~ A method comprising:
providing an extract of Coeloglossum viride (L.) Hartm. var. bracteatum (Willd.) Richter;
and
utilizing the extract in the manufacture of [[the]] drugs for preventing or treating dementia.

9. (Currently Amended) The [[use]] method according to claim 8, characterized in that said dementia includes Alzheimer' disease, vascular dementia and learning and memory obstacle.

10. (Currently Amended) A pharmaceutical composition, comprising an effective

amount of extracts according to claim 8 and a pharmaceutically acceptable carrier, wherein said pharmaceutically acceptable carrier is not ethanol.

11. (Original) The pharmaceutical composition according to claim 10, characterized in that said pharmaceutical composition may be in the form of tablets, capsules, pills, injectable solutions, sustained released formulation, controled released formulation and various microparticle systems.

12. (Currently Amended) The [[use]] method according to claim 2, characterized in that said compounds include stereo-isomers and pharmaceutical acceptable salts.

13. (Currently Amended) The [[use]] method according to claim 3, characterized in that said compounds include stereo-isomers and pharmaceutical acceptable salts.

14. (Currently Amended) A pharmaceutical composition, comprising an effective amount of any one of the compounds according to claim 2 and a pharmaceutically acceptable carrier, wherein said pharmaceutically acceptable carrier is not water.

15. (Currently Amended) A pharmaceutical composition, comprising an effective amount of any one of the compounds according to claim 3 and a pharmaceutically acceptable carrier, wherein said pharmaceutically acceptable carrier is not water.

16. (Currently Amended) A pharmaceutical composition, comprising an effective amount of any one of the compounds according to claim 4 and a pharmaceutically acceptable carrier, wherein said pharmaceutically acceptable carrier is not water.